Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
Clinical trial NCT07438600 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07438600
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-24
- Primary completion
- 2027-02-28
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.